Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 785 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gene Expression Clear all

Conditions: Breast Cancer
Interventions: Abraxane, Bevacizumab, Carboplatin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 4
States / cities: Charlotte, North Carolina • Concord, North Carolina • Durham, North Carolina + 1 more

Conditions: Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced, Pancreatic Adenocarcinoma Advanced or Metastatic, Lung Adenocarcinoma Metastatic, Cholangiocarcinoma Advanced, Cholangiocarcinoma Non-resectable, Mesothelin-expressing Advanced Cancers, Mesothelin-positive Advanced Malignant Solid Tumors, Colorectal Cancer
Interventions: CT-95; Drug
Lead sponsor: Context Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: Denver, Colorado • Chicago, Illinois • Grand Rapids, Michigan + 4 more

Conditions: Gene Expression
Interventions: Sculptra, Radiesse Plus; Device
Lead sponsor: Galderma R&D; Industry
Eligibility: 22 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer
Interventions: MammaPrint, BluePrint, and Full-Genome Testing; Diagnostic Test
Lead sponsor: Agendia; Industry
Eligibility: 18 Years and older
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2037
U.S. locations: 130
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 107 more

Conditions: Non Hodgkin Lymphoma, High-grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Interventions: Cyclophosphamide, Alemtuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: PI3K-beta Inhibitor GSK2636771; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Subject, Intracranial Neoplasm, Glioblastoma
Interventions: Fluorine F 18 DASA-23, Positron Emission Tomography; Drug · Procedure
Lead sponsor: Guido A. Davidzon, MD, SM; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Non-Hodgkin's Disease
Interventions: Nivolumab, Brentuximab Vedotin; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 15 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 16
States / cities: Birmingham, Alabama • Miami, Florida • Tampa, Florida + 12 more

Conditions: Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Lung Cancer
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 3,087 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Autism
Interventions: Not listed
Lead sponsor: SynapDx; Industry
Eligibility: 18 Months to 5 Years
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Meibomian Gland Dysfunction
Interventions: Meibomian gland (MG) expression; Procedure
Lead sponsor: University of the Incarnate Word; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Central Nervous System Tumor, Pediatric
Interventions: Not listed
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: Up to 3 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more

Conditions: Cardiovascular Disease
Interventions: Decoding Your Diet; Genetic
Lead sponsor: Morehouse School of Medicine; Other
Eligibility: 40 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy Volunteers
Interventions: Photographic Review; Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 393 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Saratoga Springs, New York

Conditions: Healthy
Interventions: Rose hips extract + blueberry/blackberry extract + resveravine, Rose hips extract + blueberry/blackberry extract + Aframomum melegueta extract, Rose hips extract + resveravine + Aframomum melegueta extract; Drug
Lead sponsor: Access Business Group; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 8
States / cities: Artesia, California • Buena Park, California • Burbank, California + 4 more

Conditions: Heart Transplant Rejection
Interventions: MMDx diagnostic test, Prospera, HLA antibody; Diagnostic Test
Lead sponsor: University of Alberta; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 6
States / cities: Little Rock, Arkansas • Tampa, Florida • West New York, New Jersey + 3 more

Conditions: Healthy
Interventions: Frankincense essential oil + boswellic acid supplement, Frankincense essential oil supplement; Dietary Supplement
Lead sponsor: dōTERRA International; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Pleasant Grove, Utah

Conditions: Skin Basal Cell Carcinoma
Interventions: Itraconazole, Placebo; Drug · Other
Lead sponsor: Jean Yuh Tang; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Healthy
Interventions: 'Rosy Red Valencia' sweet orange, 'Olinda Valencia' sweet oranges; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 25 Years to 40 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Davis, California

Conditions: Mucositis, Multiple Myeloma, Amyloidosis, Oral Mucositis
Interventions: Melphalan kinetic study, Oral bacterial study, Gene expression study; Other · Genetic
Lead sponsor: Sherif S. Farag; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: HIV Infection
Interventions: PENNVAX-B, GENEVAX IL-12-4532, PLACEBO, IL-15 adjuvant; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 50 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Preterm Birth, Premature Rupture of Membranes
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Not listed
Enrollment: 6,838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2016
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Orthopaedic Trauma, Chronic Pain, Musculoskeletal Injury
Interventions: Emotional Awareness and Expression Therapy; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: PreDiabetes
Interventions: Semaglutide; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Brownsville, Texas

Search by objective public record fields.

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Cyclophosphamide and Alemtuzumab In Lymphoma

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Blood Collection From Individuals With Lung Disease for Genetic Studies

SynapDx Autism Gene Expression Analysis Study

The Impact of Dry Eye Syndrome on Metrics of Low Contrast Vision Before and After Meibomian Gland Expression

Genetic Study of Brain Tumors in Young Children

Decoding Your Diet (DYD)

Perception of Facial Expression in Subjects With and Without Crow's Feet Lines

Study to Evaluate the Effect of Botanical Dietary Supplements on Inflammation in Healthy People

Trifecta-Heart cfDNA-MMDx Study

Frankincense Supplements and Inflammation

Topical Itraconazole in Treating Patients With Basal Cell Cancer

Evaluation of the Antioxidant and Anti-Inflammatory Capacities of the 'Rosy Red Valencia' and 'Olinda Valencia' Sweet Orange Varieties in Healthy Subjects

Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant

PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection

Microarray Expression Profiling to Identify Stereotypic mRNA Profiles in Human Parturition

Emotional Awareness and Expression Therapy for People With Persistent Pain Following Orthopedic Trauma

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes